Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?

Evangelos Papanastasiou,Sukhwinder S Shergill
DOI: https://doi.org/10.1177/02698811211000773
2021-04-28
Journal of Psychopharmacology
Abstract:To the Editor,Drug discovery and development in CNS has been largely unsuccessful for several decades despite the pressure applied by significant unmet medical needs. This situation is typically seen in schizophrenia, where several compounds targeting negative or treatment-resistant positive symptoms did not succeed in meeting their primary clinical endpoints; more recent selected examples to include bitopertin (a glycine transporter 1 inhibitor developed by Roche as a treatment for the negative symptoms of schizophrenia), LuAF11167 (a phosphodiesterase 10A enzyme selective inhibitor developed by Lundbeck as a monotherapy for schizophrenia) and LuAF35700 (a dopamine, serotonin, noradrenaline receptor antagonist developed by Lundbeck for the management of treatment-resistant schizophrenia) and roluperidone (a 5-HT2A and σ2 receptor antagonist developed by Minerva as a monotherapy for schizophrenia). Given the elevated failure rates, a number of pharmaceutical companies have withdrawn their activities from schizophrenia, while declining support by the National Institute of Mental Health (NIMH, USA) has further aggravated the problem, thus limiting the treatment options available for patients and clinicians (Torrey et al., 2018).
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
What problem does this paper attempt to address?